Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.

Journal of the National Cancer Institute - 1 Jun 1994

Schneider J, Rubio M P, Barbazán M J, Rodriguez-Escudero F J, Seizinger B R, Castresana J S

Abstract excerpt

BACKGROUND: Overexpression of P-glycoprotein has been associated with a worse prognosis for some groups of patients not receiving chemotherapy. Recently, it has been demonstrated that in vitro both c-Ha-Ras overexpression and mutant p53 overexpression do activate the MDR1 gene (also known as PGY1) in murine NIH 3T3 cells. This direct connection between oncogenic activation, antioncogenic malfunctioning (presence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Carrier Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Genes, p53

Share to Membrane Glycoproteins

Share to Mutation

Share to Polymerase Chain Reaction

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 7910219
DOI: 10.1093/jnci/86.11.850

Genes

ERBB2
NCL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.PMID 7910219Read ↗

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study.Semantic proximity Read ↗

Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.Semantic proximity Read ↗

Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer.Semantic proximity Read ↗

[Analysis of p53, MDR-1, and GST-pi expression in endometrial carcinoma].Semantic proximity Read ↗

p53 tumor suppressor gene protein expression in cervical cancer: relationship to prognosis.Semantic proximity Read ↗

Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.Semantic proximity Read ↗

Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.Semantic proximity Read ↗

Overexpression and mutation of p53 in epithelial ovarian cancer.Semantic proximity Read ↗

Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.Semantic proximity Read ↗

Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.Semantic proximity Read ↗

Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels.Semantic proximity Read ↗

p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.